| Company Name: |
Energy Chemical |
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing@energy-chemical.com |
|
| Product Name: | COP-1 | | Synonyms: | [L-ALA, L-GLU, L-LYS HBR, L-TYR]N;COP-1;POLY(ALA, GLU, LYS, TYR) HYDROBROMIDE;(t,g)-a-l;poly(ala;POLY(ALA, GLU, LYS, TYR) 6:2:5:1*HYDROBR OMIDE MOL.;Copaxone;(l-ala, l-glu, l-lys, l-tyr)n ·hbr | | CAS: | 28704-27-0 | | MF: | C23H41N5O11 | | MW: | 563.61 | | EINECS: | | | Product Categories: | | | Mol File: | 28704-27-0.mol |  |
| | COP-1 Chemical Properties |
| storage temp. | −20°C | | form | powder | | color | white to off-white | | InChIKey | YLOCGHYTXIINAI-XKUOMLDTSA-N | | SMILES | N[C@@H](CCCCN)C(=O)O.N[C@@H](Cc1ccc(cc1)O)C(=O)O.N[C@@H](CCC(=O)O)C(=O)O.N[C@@H](C)C(=O)O |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | COP-1 Usage And Synthesis |
| Description | Copaxone was launched in Israel and the US for treatment of relapsingremitting
multiple sclerosis. The amino acid polymer is prepared from the Ncarboxyanhydrides
of Tyr, Ala, γ-benzylglutamate and ε,N-trifluoroacetyllysine followed
by deprotection. Structurally, the random polymer, with a residue molar ratio of
6.0:1.9:4.7:1.O=Ala:Glu:Lys:Tyr, simulates myelin basic protein (MBP). This gives it
immunomodulating and immunosuppressive activity (antigen specific so not a general
immunosuppressive). The mechanism involves binding to MHC class Ⅱ (I-A/DR)
molecules which results both in competition with myelin antigens for T-cell activation
and in induction of specific suppressor cells of the Th2 type. Therefore, the antigenspecific
interaction gives rise to a reduced probability of long-term damage to the
immune system. The competition with MBP and other myelin-associated antigens
inhibits T-cell responses to MBP, and the binding occurs with high efficiency, fast rates
and is non-species specific. It resulted in a 29% reduction in relapse rate and is most
effective in patients with less accumulated neurologic disability. | | Originator | Yeda (Israel) | | History |
Cop 1(Copaxone®) was discovered by Arnon and Sela, it was submitted by the TEVA Pharmaceutical Company to the FDA for approval, under the name of Copaxone, on June 14, 1995. In December 1996, following nearly three decades of research, the multiple sclerosis drug copolymer-1 (Copaxone®) became one of the first Israeli medications to receive the approval of the U.S. Food and Drug Administration. Prof. Ruth Arnon, the Institute's Vice President for International Scientific Relations, who, along with Weizmann Institute colleagues Prof. Michael Sela and Dr. Dvora Teitelbaum, originally synthesized and developed copolymer-1, recently documented the drug's dramatic history in the scientific journal Immunology Letters.
| | Brand name | Copaxone |
| | COP-1 Preparation Products And Raw materials |
|